Drug Sponsors

Sapiens attracts $9.8M for next generation deep brain stimulation therapy

Wednesday, February 27, 2013 10:01 AM

Sapiens Steering Brain Stimulation, an emerging medical technology company developing brain stimulation products, has raised $9.8 million from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round. The proceeds will be used for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson's disease (PD) and other functional brain disorders.

More... »

Elan acknowledges Royalty’s proposal

Monday, February 25, 2013 10:57 AM

The board of Elan, a biotechnology company based in Ireland, has acknowledged the announcement by Royalty Management regarding an indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of Elan.

More... »

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Ambit Biosciences registers for proposed IPO

Friday, February 22, 2013 10:47 AM

Ambit Biosciences, a privately held biopharmaceutical company, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for an initial public offering of its common stock on the NASDAQ stock market.

More... »

Aerial Biopharma closes second tranche of Series A for narcolepsy drug

Wednesday, February 20, 2013 03:19 PM

Aerial BioPharma, a privately held biopharmaceutical company based in Morrisville, N.C., has completed the second tranche of its $12 million dollar Series A financing.  The company has now raised $9.5 million, with the third and final tranche of the Series A to be completed in the fourth quarter of 2013. 

More... »

Sophiris Bio files for proposed IPO

Wednesday, February 20, 2013 11:24 AM

Sophiris Bio, a La Jolla, Calif.-based biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market.

More... »

Novartis, Dr. Vasella cancel non-compete agreement

Wednesday, February 20, 2013 09:29 AM

The Novartis board of directors and Dr. Daniel Vasella, chairman of the company’s board, have agreed to cancel Vasella’s non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after Vasella steps down as chairman of the board on February 22, 2013.

More... »

Dako, Pfizer collaborate on companion diagnostics

Thursday, February 14, 2013 08:00 AM

Dako, a tissue-based cancer diagnostics company based in Denmark, has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.

More... »

Reckitt Benckiser, BMS collaborate on Latam OTC

Wednesday, February 13, 2013 02:33 PM

Reckitt Benckiser Group has signed a three year collaboration agreement with Bristol-Myers Squibb (BMS) for a number of market-leading over-the-counter (OTC) consumer health care brands in Brazil, Mexico and certain other parts of Latin America, with an option to purchase at the end of the three year period.

More... »

e-Therapeutics to raise $62 million for cancer drug, network pharmacology platform

Monday, February 11, 2013 02:08 PM

Drug discovery and development company e-Therapeutics has proposed raising $62 million through an issue of new ordinary shares to existing and new institutional investors.

More... »